Figure 5.

In vivo depletion of Gr-1 positive MDSCs abrogates GSK872-mediated hepatoprotection. Mice were given anti-Gr-1 depleting antibody (250 µg) or control IgG (250 µg), treated with GSK872 or vehicle 36 h later, and followed by administration of ConA or PBS (n=6 per group). (A) Flow cytometry analysis of CD11b⁺Gr-1⁺ MDSCs in livers (up) and spleens (down). Representative scatter plots (left) are presented, and the histogram (right) represents the percentages of CD11b⁺Gr-1⁺ MDSCs. (B) Serum levels of ALT and AST were measured 12 h after ConA treatment. (C) Liver index (left) and spleen index (right) were determined 12 h after ConA treatment. (D) Representative photomicrographs (H&E staining; original magnification 200×; scale bars, 50 μm; up) and perusal images (down) of livers. All the values are shown as mean ± SD. ns., not significant; *P < 0.05, **P < 0.01.